nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ATP4A—hematologic cancer	0.217	0.693	CbGaD
Lansoprazole—ABCG2—hematologic cancer	0.0681	0.217	CbGaD
Lansoprazole—CYP1B1—Procarbazine—hematologic cancer	0.0319	0.0729	CbGbCtD
Lansoprazole—ABCB1—hematologic cancer	0.0283	0.0903	CbGaD
Lansoprazole—CYP1B1—Daunorubicin—hematologic cancer	0.0171	0.0391	CbGbCtD
Lansoprazole—CYP4A11—Cisplatin—hematologic cancer	0.016	0.0367	CbGbCtD
Lansoprazole—CYP2C18—Ifosfamide—hematologic cancer	0.0145	0.0331	CbGbCtD
Lansoprazole—ABCG2—Clofarabine—hematologic cancer	0.0139	0.0317	CbGbCtD
Lansoprazole—CYP4A11—Dexamethasone—hematologic cancer	0.013	0.0297	CbGbCtD
Lansoprazole—CYP1B1—Dasatinib—hematologic cancer	0.0105	0.0241	CbGbCtD
Lansoprazole—CYP1B1—Mitoxantrone—hematologic cancer	0.0104	0.0238	CbGbCtD
Lansoprazole—CYP1A2—Anagrelide—hematologic cancer	0.00824	0.0189	CbGbCtD
Lansoprazole—CYP1A1—Methoxsalen—hematologic cancer	0.00824	0.0189	CbGbCtD
Lansoprazole—ABCG2—Daunorubicin—hematologic cancer	0.00812	0.0186	CbGbCtD
Lansoprazole—CYP1A1—Bortezomib—hematologic cancer	0.00784	0.0179	CbGbCtD
Lansoprazole—CYP1A1—Daunorubicin—hematologic cancer	0.0075	0.0172	CbGbCtD
Lansoprazole—ABCG2—Teniposide—hematologic cancer	0.00706	0.0162	CbGbCtD
Lansoprazole—CYP1A1—Thalidomide—hematologic cancer	0.00683	0.0156	CbGbCtD
Lansoprazole—ABCG2—Cladribine—hematologic cancer	0.00677	0.0155	CbGbCtD
Lansoprazole—ABCG2—Imatinib—hematologic cancer	0.00622	0.0142	CbGbCtD
Lansoprazole—CYP1A1—Dacarbazine—hematologic cancer	0.00587	0.0134	CbGbCtD
Lansoprazole—ABCG2—Nilotinib—hematologic cancer	0.00565	0.0129	CbGbCtD
Lansoprazole—CYP1B1—Dexamethasone—hematologic cancer	0.00538	0.0123	CbGbCtD
Lansoprazole—CYP2C9—Bexarotene—hematologic cancer	0.00515	0.0118	CbGbCtD
Lansoprazole—ABCG2—Dasatinib—hematologic cancer	0.005	0.0114	CbGbCtD
Lansoprazole—ABCB1—Lenalidomide—hematologic cancer	0.00499	0.0114	CbGbCtD
Lansoprazole—ABCG2—Mitoxantrone—hematologic cancer	0.00494	0.0113	CbGbCtD
Lansoprazole—CYP1A1—Dasatinib—hematologic cancer	0.00461	0.0106	CbGbCtD
Lansoprazole—CYP2C8—Bortezomib—hematologic cancer	0.00452	0.0104	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—hematologic cancer	0.00447	0.0102	CbGbCtD
Lansoprazole—CYP2D6—Lomustine—hematologic cancer	0.00438	0.01	CbGbCtD
Lansoprazole—CYP1A2—Carmustine—hematologic cancer	0.00433	0.00991	CbGbCtD
Lansoprazole—CYP2C9—Idarubicin—hematologic cancer	0.00426	0.00976	CbGbCtD
Lansoprazole—CYP2D6—Idarubicin—hematologic cancer	0.0039	0.00893	CbGbCtD
Lansoprazole—ABCG2—Irinotecan—hematologic cancer	0.00389	0.00889	CbGbCtD
Lansoprazole—CYP2C19—Bortezomib—hematologic cancer	0.00379	0.00869	CbGbCtD
Lansoprazole—CYP1A2—Methoxsalen—hematologic cancer	0.00368	0.00843	CbGbCtD
Lansoprazole—CYP1A2—Bortezomib—hematologic cancer	0.0035	0.00801	CbGbCtD
Lansoprazole—CYP2C8—Ifosfamide—hematologic cancer	0.00347	0.00794	CbGbCtD
Lansoprazole—ABCG2—Vincristine—hematologic cancer	0.0034	0.00777	CbGbCtD
Lansoprazole—CYP1A2—Daunorubicin—hematologic cancer	0.00335	0.00767	CbGbCtD
Lansoprazole—CYP2D6—Hydroxyurea—hematologic cancer	0.00332	0.00759	CbGbCtD
Lansoprazole—CYP2C19—Thalidomide—hematologic cancer	0.00331	0.00757	CbGbCtD
Lansoprazole—CYP1A2—Alitretinoin—hematologic cancer	0.00328	0.00751	CbGbCtD
Lansoprazole—ABCG2—Cisplatin—hematologic cancer	0.00317	0.00725	CbGbCtD
Lansoprazole—CYP2C9—Bortezomib—hematologic cancer	0.00315	0.00722	CbGbCtD
Lansoprazole—CYP2C19—Teniposide—hematologic cancer	0.00315	0.00722	CbGbCtD
Lansoprazole—ABCG2—Etoposide—hematologic cancer	0.00311	0.00712	CbGbCtD
Lansoprazole—CYP1A2—Thalidomide—hematologic cancer	0.00305	0.00698	CbGbCtD
Lansoprazole—CYP2C8—Nilotinib—hematologic cancer	0.00301	0.00689	CbGbCtD
Lansoprazole—CYP3A4—Bexarotene—hematologic cancer	0.00299	0.00685	CbGbCtD
Lansoprazole—ABCB1—Daunorubicin—hematologic cancer	0.00293	0.0067	CbGbCtD
Lansoprazole—CYP2C19—Ifosfamide—hematologic cancer	0.00291	0.00666	CbGbCtD
Lansoprazole—CYP2D6—Bortezomib—hematologic cancer	0.00288	0.0066	CbGbCtD
Lansoprazole—ABCB1—Alitretinoin—hematologic cancer	0.00287	0.00657	CbGbCtD
Lansoprazole—CYP3A4—Lomustine—hematologic cancer	0.00278	0.00637	CbGbCtD
Lansoprazole—CYP3A4—Busulfan—hematologic cancer	0.00278	0.00637	CbGbCtD
Lansoprazole—CYP2C19—Imatinib—hematologic cancer	0.00278	0.00636	CbGbCtD
Lansoprazole—CYP2C9—Thalidomide—hematologic cancer	0.00275	0.00629	CbGbCtD
Lansoprazole—CYP1A2—Dacarbazine—hematologic cancer	0.00262	0.006	CbGbCtD
Lansoprazole—CYP2C9—Teniposide—hematologic cancer	0.00262	0.006	CbGbCtD
Lansoprazole—CYP1A2—Imatinib—hematologic cancer	0.00257	0.00587	CbGbCtD
Lansoprazole—ABCG2—Dexamethasone—hematologic cancer	0.00256	0.00586	CbGbCtD
Lansoprazole—CYP3A4—Thiotepa—hematologic cancer	0.00248	0.00568	CbGbCtD
Lansoprazole—CYP2C9—Ifosfamide—hematologic cancer	0.00242	0.00554	CbGbCtD
Lansoprazole—CYP1A1—Dexamethasone—hematologic cancer	0.00236	0.00541	CbGbCtD
Lansoprazole—CYP2C9—Imatinib—hematologic cancer	0.00231	0.00529	CbGbCtD
Lansoprazole—ABCB1—Imatinib—hematologic cancer	0.00224	0.00513	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—hematologic cancer	0.00212	0.00486	CbGbCtD
Lansoprazole—CYP2D6—Imatinib—hematologic cancer	0.00211	0.00484	CbGbCtD
Lansoprazole—CYP2C9—Nilotinib—hematologic cancer	0.0021	0.00481	CbGbCtD
Lansoprazole—CYP1A2—Dasatinib—hematologic cancer	0.00206	0.00472	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—hematologic cancer	0.00206	0.00471	CbGbCtD
Lansoprazole—ABCB1—Nilotinib—hematologic cancer	0.00204	0.00467	CbGbCtD
Lansoprazole—ABCB1—Vinorelbine—hematologic cancer	0.00202	0.00463	CbGbCtD
Lansoprazole—CYP3A4—Methoxsalen—hematologic cancer	0.00193	0.00441	CbGbCtD
Lansoprazole—CYP2D6—Nilotinib—hematologic cancer	0.00192	0.0044	CbGbCtD
Lansoprazole—CYP2D6—Vinorelbine—hematologic cancer	0.0019	0.00436	CbGbCtD
Lansoprazole—CYP3A4—Bortezomib—hematologic cancer	0.00183	0.0042	CbGbCtD
Lansoprazole—CYP2C19—Prednisone—hematologic cancer	0.00183	0.00419	CbGbCtD
Lansoprazole—ABCB1—Dasatinib—hematologic cancer	0.0018	0.00412	CbGbCtD
Lansoprazole—ABCB1—Mitoxantrone—hematologic cancer	0.00178	0.00407	CbGbCtD
Lansoprazole—CYP3A4—Daunorubicin—hematologic cancer	0.00175	0.00402	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—hematologic cancer	0.00166	0.00379	CbGbCtD
Lansoprazole—ABCB1—Betamethasone—hematologic cancer	0.00159	0.00363	CbGbCtD
Lansoprazole—ABCB1—Gemcitabine—hematologic cancer	0.00157	0.0036	CbGbCtD
Lansoprazole—ABCB1—Prednisolone—hematologic cancer	0.00156	0.00358	CbGbCtD
Lansoprazole—CYP3A4—Cytarabine—hematologic cancer	0.00155	0.00354	CbGbCtD
Lansoprazole—CYP3A4—Teniposide—hematologic cancer	0.00152	0.00349	CbGbCtD
Lansoprazole—ABCB1—Prednisone—hematologic cancer	0.00148	0.00338	CbGbCtD
Lansoprazole—CYP3A4—Ifosfamide—hematologic cancer	0.00141	0.00322	CbGbCtD
Lansoprazole—ABCB1—Irinotecan—hematologic cancer	0.0014	0.00321	CbGbCtD
Lansoprazole—CYP2C8—Dexamethasone—hematologic cancer	0.00136	0.00312	CbGbCtD
Lansoprazole—CYP3A4—Imatinib—hematologic cancer	0.00134	0.00308	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—hematologic cancer	0.00128	0.00294	CbGbCtD
Lansoprazole—CYP3A4—Ruxolitinib—hematologic cancer	0.00127	0.0029	CbGbCtD
Lansoprazole—ABCB1—Vinblastine—hematologic cancer	0.00125	0.00285	CbGbCtD
Lansoprazole—ABCB1—Vincristine—hematologic cancer	0.00122	0.0028	CbGbCtD
Lansoprazole—CYP3A4—Nilotinib—hematologic cancer	0.00122	0.0028	CbGbCtD
Lansoprazole—CYP3A4—Vinorelbine—hematologic cancer	0.00121	0.00277	CbGbCtD
Lansoprazole—CYP2C9—Cisplatin—hematologic cancer	0.00118	0.00269	CbGbCtD
Lansoprazole—CYP2D6—Vinblastine—hematologic cancer	0.00117	0.00269	CbGbCtD
Lansoprazole—ATP4A—hematopoietic system—hematologic cancer	0.00117	0.0957	CbGeAlD
Lansoprazole—CYP2C19—Dexamethasone—hematologic cancer	0.00114	0.00262	CbGbCtD
Lansoprazole—ABCB1—Cisplatin—hematologic cancer	0.00114	0.00261	CbGbCtD
Lansoprazole—ABCB1—Etoposide—hematologic cancer	0.00112	0.00257	CbGbCtD
Lansoprazole—CYP3A4—Triamcinolone—hematologic cancer	0.00111	0.00254	CbGbCtD
Lansoprazole—CYP3A4—Dasatinib—hematologic cancer	0.00108	0.00247	CbGbCtD
Lansoprazole—CYP3A4—Mitoxantrone—hematologic cancer	0.00107	0.00244	CbGbCtD
Lansoprazole—CYP2C9—Dexamethasone—hematologic cancer	0.000951	0.00218	CbGbCtD
Lansoprazole—CYP3A4—Betamethasone—hematologic cancer	0.00095	0.00218	CbGbCtD
Lansoprazole—CYP3A4—Prednisolone—hematologic cancer	0.000938	0.00215	CbGbCtD
Lansoprazole—ABCB1—Dexamethasone—hematologic cancer	0.000923	0.00211	CbGbCtD
Lansoprazole—CYP3A4—Prednisone—hematologic cancer	0.000885	0.00203	CbGbCtD
Lansoprazole—CYP2D6—Dexamethasone—hematologic cancer	0.000869	0.00199	CbGbCtD
Lansoprazole—MAPT—testis—hematologic cancer	0.000863	0.0707	CbGeAlD
Lansoprazole—CYP3A4—Irinotecan—hematologic cancer	0.000839	0.00192	CbGbCtD
Lansoprazole—Esomeprazole—ATP4A—hematologic cancer	0.000795	0.237	CrCbGaD
Lansoprazole—ATP4A—blood—hematologic cancer	0.000775	0.0634	CbGeAlD
Lansoprazole—ABCB1—Doxorubicin—hematologic cancer	0.000765	0.00175	CbGbCtD
Lansoprazole—CYP3A4—Vinblastine—hematologic cancer	0.000746	0.00171	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—hematologic cancer	0.000741	0.0017	CbGbCtD
Lansoprazole—CYP3A4—Vincristine—hematologic cancer	0.000734	0.00168	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—hematologic cancer	0.000721	0.00165	CbGbCtD
Lansoprazole—CYP3A4—Etoposide—hematologic cancer	0.000672	0.00154	CbGbCtD
Lansoprazole—ATP4A—testis—hematologic cancer	0.000641	0.0525	CbGeAlD
Lansoprazole—MAPT—lymph node—hematologic cancer	0.000626	0.0512	CbGeAlD
Lansoprazole—Pantoprazole—ATP4A—hematologic cancer	0.000574	0.171	CrCbGaD
Lansoprazole—Rabeprazole—ATP4A—hematologic cancer	0.000574	0.171	CrCbGaD
Lansoprazole—CYP3A4—Dexamethasone—hematologic cancer	0.000553	0.00127	CbGbCtD
Lansoprazole—Omeprazole—ATP4A—hematologic cancer	0.000468	0.14	CrCbGaD
Lansoprazole—CYP1B1—hematopoietic system—hematologic cancer	0.000466	0.0381	CbGeAlD
Lansoprazole—CYP3A4—Doxorubicin—hematologic cancer	0.000459	0.00105	CbGbCtD
Lansoprazole—CYP2C19—hematopoietic system—hematologic cancer	0.000409	0.0334	CbGeAlD
Lansoprazole—CYP2C8—hematopoietic system—hematologic cancer	0.000357	0.0292	CbGeAlD
Lansoprazole—CYP1B1—gonad—hematologic cancer	0.000354	0.029	CbGeAlD
Lansoprazole—CYP1A2—hematopoietic system—hematologic cancer	0.000334	0.0273	CbGeAlD
Lansoprazole—CYP1A1—hematopoietic system—hematologic cancer	0.000329	0.0269	CbGeAlD
Lansoprazole—CYP2C9—hematopoietic system—hematologic cancer	0.000317	0.0259	CbGeAlD
Lansoprazole—CYP1B1—blood—hematologic cancer	0.000308	0.0253	CbGeAlD
Lansoprazole—Omeprazole—ABCC3—hematologic cancer	0.000302	0.09	CrCbGaD
Lansoprazole—CYP2C19—blood—hematologic cancer	0.000271	0.0222	CbGeAlD
Lansoprazole—CYP1B1—lung—hematologic cancer	0.00027	0.0221	CbGeAlD
Lansoprazole—CYP1B1—testis—hematologic cancer	0.000255	0.0209	CbGeAlD
Lansoprazole—CYP3A4—hematopoietic system—hematologic cancer	0.000242	0.0198	CbGeAlD
Lansoprazole—CYP2D6—hematopoietic system—hematologic cancer	0.000238	0.0195	CbGeAlD
Lansoprazole—CYP2C8—blood—hematologic cancer	0.000236	0.0193	CbGeAlD
Lansoprazole—ABCG2—blood—hematologic cancer	0.00023	0.0188	CbGeAlD
Lansoprazole—ABCG2—bone marrow—hematologic cancer	0.000222	0.0182	CbGeAlD
Lansoprazole—CYP1A2—blood—hematologic cancer	0.000221	0.0181	CbGeAlD
Lansoprazole—CYP1A1—blood—hematologic cancer	0.000218	0.0179	CbGeAlD
Lansoprazole—CYP2C9—blood—hematologic cancer	0.00021	0.0172	CbGeAlD
Lansoprazole—ABCG2—lung—hematologic cancer	0.000201	0.0165	CbGeAlD
Lansoprazole—CYP2C8—testis—hematologic cancer	0.000195	0.016	CbGeAlD
Lansoprazole—CYP1A2—lung—hematologic cancer	0.000194	0.0159	CbGeAlD
Lansoprazole—CYP1A1—lung—hematologic cancer	0.000191	0.0156	CbGeAlD
Lansoprazole—ABCG2—testis—hematologic cancer	0.00019	0.0156	CbGeAlD
Lansoprazole—CYP1B1—lymph node—hematologic cancer	0.000185	0.0151	CbGeAlD
Lansoprazole—Rabeprazole—ABCG2—hematologic cancer	0.00018	0.0536	CrCbGaD
Lansoprazole—Pantoprazole—ABCG2—hematologic cancer	0.00018	0.0536	CrCbGaD
Lansoprazole—ABCB1—hematopoietic system—hematologic cancer	0.000171	0.014	CbGeAlD
Lansoprazole—CYP3A4—blood—hematologic cancer	0.00016	0.0131	CbGeAlD
Lansoprazole—CYP2D6—blood—hematologic cancer	0.000157	0.0129	CbGeAlD
Lansoprazole—Omeprazole—ABCG2—hematologic cancer	0.000147	0.0437	CrCbGaD
Lansoprazole—ABCG2—lymph node—hematologic cancer	0.000138	0.0113	CbGeAlD
Lansoprazole—CYP1A1—lymph node—hematologic cancer	0.000131	0.0107	CbGeAlD
Lansoprazole—CYP2D6—testis—hematologic cancer	0.00013	0.0107	CbGeAlD
Lansoprazole—ABCB1—gonad—hematologic cancer	0.00013	0.0106	CbGeAlD
Lansoprazole—ABCB1—blood—hematologic cancer	0.000113	0.00927	CbGeAlD
Lansoprazole—ABCB1—bone marrow—hematologic cancer	0.00011	0.00897	CbGeAlD
Lansoprazole—ABCB1—lung—hematologic cancer	9.93e-05	0.00813	CbGeAlD
Lansoprazole—ABCB1—testis—hematologic cancer	9.37e-05	0.00767	CbGeAlD
Lansoprazole—Pantoprazole—ABCB1—hematologic cancer	7.48e-05	0.0223	CrCbGaD
Lansoprazole—ABCB1—lymph node—hematologic cancer	6.79e-05	0.00556	CbGeAlD
Lansoprazole—Omeprazole—ABCB1—hematologic cancer	6.1e-05	0.0182	CrCbGaD
Lansoprazole—Flatulence—Epirubicin—hematologic cancer	7.16e-06	4.32e-05	CcSEcCtD
Lansoprazole—Tension—Epirubicin—hematologic cancer	7.13e-06	4.31e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.12e-06	4.3e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Betamethasone—hematologic cancer	7.12e-06	4.3e-05	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—hematologic cancer	7.11e-06	4.3e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Triamcinolone—hematologic cancer	7.07e-06	4.27e-05	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—hematologic cancer	7.05e-06	4.26e-05	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—hematologic cancer	7.02e-06	4.25e-05	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—hematologic cancer	7e-06	4.23e-05	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—hematologic cancer	7e-06	4.23e-05	CcSEcCtD
Lansoprazole—Dizziness—Etoposide—hematologic cancer	6.99e-06	4.23e-05	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—hematologic cancer	6.98e-06	4.22e-05	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—hematologic cancer	6.97e-06	4.21e-05	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—hematologic cancer	6.97e-06	4.21e-05	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—hematologic cancer	6.96e-06	4.2e-05	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—hematologic cancer	6.95e-06	4.2e-05	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—hematologic cancer	6.93e-06	4.19e-05	CcSEcCtD
Lansoprazole—Urticaria—Dexamethasone—hematologic cancer	6.91e-06	4.18e-05	CcSEcCtD
Lansoprazole—Urticaria—Betamethasone—hematologic cancer	6.91e-06	4.18e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.9e-06	4.17e-05	CcSEcCtD
Lansoprazole—Dizziness—Prednisolone—hematologic cancer	6.9e-06	4.17e-05	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—hematologic cancer	6.9e-06	4.17e-05	CcSEcCtD
Lansoprazole—Asthenia—Triamcinolone—hematologic cancer	6.88e-06	4.16e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Betamethasone—hematologic cancer	6.88e-06	4.16e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Dexamethasone—hematologic cancer	6.88e-06	4.16e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Dexamethasone—hematologic cancer	6.88e-06	4.16e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Betamethasone—hematologic cancer	6.88e-06	4.16e-05	CcSEcCtD
Lansoprazole—Nausea—Cisplatin—hematologic cancer	6.86e-06	4.14e-05	CcSEcCtD
Lansoprazole—Insomnia—Prednisone—hematologic cancer	6.85e-06	4.14e-05	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—hematologic cancer	6.84e-06	4.14e-05	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—hematologic cancer	6.82e-06	4.12e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Prednisone—hematologic cancer	6.8e-06	4.11e-05	CcSEcCtD
Lansoprazole—Pruritus—Triamcinolone—hematologic cancer	6.78e-06	4.1e-05	CcSEcCtD
Lansoprazole—Cough—Methotrexate—hematologic cancer	6.77e-06	4.09e-05	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—hematologic cancer	6.76e-06	4.09e-05	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—hematologic cancer	6.74e-06	4.07e-05	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—hematologic cancer	6.72e-06	4.06e-05	CcSEcCtD
Lansoprazole—Vomiting—Etoposide—hematologic cancer	6.72e-06	4.06e-05	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—hematologic cancer	6.72e-06	4.06e-05	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—hematologic cancer	6.72e-06	4.06e-05	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—hematologic cancer	6.71e-06	4.06e-05	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—hematologic cancer	6.67e-06	4.03e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Prednisone—hematologic cancer	6.67e-06	4.03e-05	CcSEcCtD
Lansoprazole—Rash—Etoposide—hematologic cancer	6.67e-06	4.03e-05	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—hematologic cancer	6.66e-06	4.03e-05	CcSEcCtD
Lansoprazole—Headache—Etoposide—hematologic cancer	6.62e-06	4e-05	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—hematologic cancer	6.62e-06	4e-05	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—hematologic cancer	6.61e-06	3.99e-05	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—hematologic cancer	6.61e-06	3.99e-05	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—hematologic cancer	6.61e-06	3.99e-05	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—hematologic cancer	6.59e-06	3.99e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Prednisone—hematologic cancer	6.59e-06	3.98e-05	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—hematologic cancer	6.58e-06	3.98e-05	CcSEcCtD
Lansoprazole—Rash—Prednisolone—hematologic cancer	6.58e-06	3.97e-05	CcSEcCtD
Lansoprazole—Dermatitis—Prednisolone—hematologic cancer	6.57e-06	3.97e-05	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.56e-06	3.97e-05	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—hematologic cancer	6.55e-06	3.96e-05	CcSEcCtD
Lansoprazole—Fatigue—Prednisone—hematologic cancer	6.53e-06	3.95e-05	CcSEcCtD
Lansoprazole—Headache—Prednisolone—hematologic cancer	6.53e-06	3.95e-05	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—hematologic cancer	6.53e-06	3.95e-05	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—hematologic cancer	6.53e-06	3.94e-05	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—hematologic cancer	6.52e-06	3.94e-05	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—hematologic cancer	6.51e-06	3.94e-05	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—hematologic cancer	6.5e-06	3.93e-05	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—hematologic cancer	6.5e-06	3.93e-05	CcSEcCtD
Lansoprazole—Constipation—Prednisone—hematologic cancer	6.48e-06	3.92e-05	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—hematologic cancer	6.46e-06	3.9e-05	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—hematologic cancer	6.42e-06	3.88e-05	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—hematologic cancer	6.39e-06	3.86e-05	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—hematologic cancer	6.38e-06	3.86e-05	CcSEcCtD
Lansoprazole—Dizziness—Triamcinolone—hematologic cancer	6.34e-06	3.83e-05	CcSEcCtD
Lansoprazole—Cough—Epirubicin—hematologic cancer	6.34e-06	3.83e-05	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—hematologic cancer	6.33e-06	3.83e-05	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—hematologic cancer	6.33e-06	3.83e-05	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—hematologic cancer	6.29e-06	3.8e-05	CcSEcCtD
Lansoprazole—Infection—Methotrexate—hematologic cancer	6.29e-06	3.8e-05	CcSEcCtD
Lansoprazole—Nausea—Etoposide—hematologic cancer	6.28e-06	3.8e-05	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—hematologic cancer	6.27e-06	3.79e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisone—hematologic cancer	6.24e-06	3.77e-05	CcSEcCtD
Lansoprazole—Asthenia—Betamethasone—hematologic cancer	6.24e-06	3.77e-05	CcSEcCtD
Lansoprazole—Asthenia—Dexamethasone—hematologic cancer	6.24e-06	3.77e-05	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—hematologic cancer	6.23e-06	3.77e-05	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—hematologic cancer	6.21e-06	3.75e-05	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—hematologic cancer	6.21e-06	3.75e-05	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—hematologic cancer	6.2e-06	3.75e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Prednisone—hematologic cancer	6.2e-06	3.75e-05	CcSEcCtD
Lansoprazole—Nausea—Prednisolone—hematologic cancer	6.19e-06	3.74e-05	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—hematologic cancer	6.18e-06	3.74e-05	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—hematologic cancer	6.18e-06	3.74e-05	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—hematologic cancer	6.18e-06	3.74e-05	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—hematologic cancer	6.17e-06	3.73e-05	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—hematologic cancer	6.16e-06	3.72e-05	CcSEcCtD
Lansoprazole—Pruritus—Betamethasone—hematologic cancer	6.16e-06	3.72e-05	CcSEcCtD
Lansoprazole—Pruritus—Dexamethasone—hematologic cancer	6.16e-06	3.72e-05	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—hematologic cancer	6.15e-06	3.72e-05	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.14e-06	3.71e-05	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—hematologic cancer	6.12e-06	3.7e-05	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—hematologic cancer	6.11e-06	3.69e-05	CcSEcCtD
Lansoprazole—Vomiting—Triamcinolone—hematologic cancer	6.1e-06	3.69e-05	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—hematologic cancer	6.06e-06	3.66e-05	CcSEcCtD
Lansoprazole—Rash—Triamcinolone—hematologic cancer	6.05e-06	3.65e-05	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—hematologic cancer	6.05e-06	3.65e-05	CcSEcCtD
Lansoprazole—Dermatitis—Triamcinolone—hematologic cancer	6.04e-06	3.65e-05	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—hematologic cancer	6.04e-06	3.65e-05	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—hematologic cancer	6.04e-06	3.65e-05	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—hematologic cancer	6.03e-06	3.64e-05	CcSEcCtD
Lansoprazole—Urticaria—Prednisone—hematologic cancer	6.02e-06	3.64e-05	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—hematologic cancer	6.01e-06	3.64e-05	CcSEcCtD
Lansoprazole—Headache—Triamcinolone—hematologic cancer	6.01e-06	3.63e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Prednisone—hematologic cancer	5.99e-06	3.62e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Prednisone—hematologic cancer	5.99e-06	3.62e-05	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—hematologic cancer	5.98e-06	3.61e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Betamethasone—hematologic cancer	5.95e-06	3.6e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Dexamethasone—hematologic cancer	5.95e-06	3.6e-05	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—hematologic cancer	5.94e-06	3.59e-05	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—hematologic cancer	5.93e-06	3.58e-05	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—hematologic cancer	5.93e-06	3.58e-05	CcSEcCtD
Lansoprazole—Hypotension—Methotrexate—hematologic cancer	5.92e-06	3.58e-05	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—hematologic cancer	5.91e-06	3.57e-05	CcSEcCtD
Lansoprazole—Infection—Epirubicin—hematologic cancer	5.89e-06	3.56e-05	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—hematologic cancer	5.86e-06	3.54e-05	CcSEcCtD
Lansoprazole—Shock—Epirubicin—hematologic cancer	5.83e-06	3.52e-05	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—hematologic cancer	5.82e-06	3.52e-05	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—hematologic cancer	5.81e-06	3.51e-05	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—hematologic cancer	5.8e-06	3.51e-05	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—hematologic cancer	5.8e-06	3.51e-05	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—hematologic cancer	5.78e-06	3.5e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.77e-06	3.49e-05	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—hematologic cancer	5.76e-06	3.48e-05	CcSEcCtD
Lansoprazole—Dizziness—Dexamethasone—hematologic cancer	5.75e-06	3.48e-05	CcSEcCtD
Lansoprazole—Dizziness—Betamethasone—hematologic cancer	5.75e-06	3.48e-05	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—hematologic cancer	5.73e-06	3.46e-05	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—hematologic cancer	5.73e-06	3.46e-05	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—hematologic cancer	5.72e-06	3.46e-05	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—hematologic cancer	5.72e-06	3.46e-05	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—hematologic cancer	5.72e-06	3.46e-05	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—hematologic cancer	5.7e-06	3.45e-05	CcSEcCtD
Lansoprazole—Nausea—Triamcinolone—hematologic cancer	5.7e-06	3.44e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—hematologic cancer	5.69e-06	3.44e-05	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.68e-06	3.43e-05	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—hematologic cancer	5.65e-06	3.42e-05	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—hematologic cancer	5.65e-06	3.41e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—hematologic cancer	5.65e-06	3.41e-05	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—hematologic cancer	5.63e-06	3.4e-05	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—hematologic cancer	5.59e-06	3.38e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Prednisone—hematologic cancer	5.58e-06	3.37e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—hematologic cancer	5.57e-06	3.37e-05	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—hematologic cancer	5.54e-06	3.35e-05	CcSEcCtD
Lansoprazole—Vomiting—Betamethasone—hematologic cancer	5.53e-06	3.34e-05	CcSEcCtD
Lansoprazole—Vomiting—Dexamethasone—hematologic cancer	5.53e-06	3.34e-05	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—hematologic cancer	5.53e-06	3.34e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—hematologic cancer	5.51e-06	3.33e-05	CcSEcCtD
Lansoprazole—Rash—Dexamethasone—hematologic cancer	5.49e-06	3.32e-05	CcSEcCtD
Lansoprazole—Rash—Betamethasone—hematologic cancer	5.49e-06	3.32e-05	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—hematologic cancer	5.48e-06	3.31e-05	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—hematologic cancer	5.48e-06	3.31e-05	CcSEcCtD
Lansoprazole—Dermatitis—Betamethasone—hematologic cancer	5.48e-06	3.31e-05	CcSEcCtD
Lansoprazole—Dermatitis—Dexamethasone—hematologic cancer	5.48e-06	3.31e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.47e-06	3.3e-05	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—hematologic cancer	5.46e-06	3.3e-05	CcSEcCtD
Lansoprazole—Headache—Betamethasone—hematologic cancer	5.45e-06	3.29e-05	CcSEcCtD
Lansoprazole—Headache—Dexamethasone—hematologic cancer	5.45e-06	3.29e-05	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—hematologic cancer	5.45e-06	3.29e-05	CcSEcCtD
Lansoprazole—Asthenia—Prednisone—hematologic cancer	5.44e-06	3.29e-05	CcSEcCtD
Lansoprazole—Pain—Methotrexate—hematologic cancer	5.42e-06	3.27e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.4e-06	3.26e-05	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—hematologic cancer	5.4e-06	3.26e-05	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—hematologic cancer	5.38e-06	3.25e-05	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—hematologic cancer	5.37e-06	3.25e-05	CcSEcCtD
Lansoprazole—Pruritus—Prednisone—hematologic cancer	5.36e-06	3.24e-05	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—hematologic cancer	5.36e-06	3.24e-05	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—hematologic cancer	5.35e-06	3.23e-05	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—hematologic cancer	5.33e-06	3.22e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—hematologic cancer	5.32e-06	3.22e-05	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—hematologic cancer	5.3e-06	3.2e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—hematologic cancer	5.28e-06	3.19e-05	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—hematologic cancer	5.27e-06	3.18e-05	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—hematologic cancer	5.23e-06	3.16e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Methotrexate—hematologic cancer	5.22e-06	3.15e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—hematologic cancer	5.22e-06	3.15e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Prednisone—hematologic cancer	5.18e-06	3.13e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—hematologic cancer	5.18e-06	3.13e-05	CcSEcCtD
Lansoprazole—Nausea—Betamethasone—hematologic cancer	5.17e-06	3.12e-05	CcSEcCtD
Lansoprazole—Nausea—Dexamethasone—hematologic cancer	5.17e-06	3.12e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—hematologic cancer	5.15e-06	3.11e-05	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—hematologic cancer	5.12e-06	3.1e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.12e-06	3.09e-05	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—hematologic cancer	5.11e-06	3.09e-05	CcSEcCtD
Lansoprazole—Pain—Epirubicin—hematologic cancer	5.07e-06	3.06e-05	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—hematologic cancer	5.07e-06	3.06e-05	CcSEcCtD
Lansoprazole—Urticaria—Methotrexate—hematologic cancer	5.03e-06	3.04e-05	CcSEcCtD
Lansoprazole—Dizziness—Prednisone—hematologic cancer	5.01e-06	3.03e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—hematologic cancer	5.01e-06	3.03e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—hematologic cancer	5.01e-06	3.03e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5e-06	3.02e-05	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—hematologic cancer	4.96e-06	3e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—hematologic cancer	4.92e-06	2.98e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—hematologic cancer	4.89e-06	2.95e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—hematologic cancer	4.88e-06	2.95e-05	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—hematologic cancer	4.88e-06	2.95e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—hematologic cancer	4.85e-06	2.93e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—hematologic cancer	4.83e-06	2.92e-05	CcSEcCtD
Lansoprazole—Vomiting—Prednisone—hematologic cancer	4.82e-06	2.91e-05	CcSEcCtD
Lansoprazole—Rash—Prednisone—hematologic cancer	4.78e-06	2.89e-05	CcSEcCtD
Lansoprazole—Dermatitis—Prednisone—hematologic cancer	4.77e-06	2.89e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—hematologic cancer	4.77e-06	2.88e-05	CcSEcCtD
Lansoprazole—Headache—Prednisone—hematologic cancer	4.75e-06	2.87e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.73e-06	2.86e-05	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—hematologic cancer	4.73e-06	2.86e-05	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—hematologic cancer	4.71e-06	2.85e-05	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—hematologic cancer	4.69e-06	2.83e-05	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—hematologic cancer	4.69e-06	2.83e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—hematologic cancer	4.69e-06	2.83e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—hematologic cancer	4.69e-06	2.83e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—hematologic cancer	4.67e-06	2.82e-05	CcSEcCtD
Lansoprazole—Asthenia—Methotrexate—hematologic cancer	4.54e-06	2.75e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—hematologic cancer	4.52e-06	2.73e-05	CcSEcCtD
Lansoprazole—Nausea—Prednisone—hematologic cancer	4.5e-06	2.72e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.48e-06	2.71e-05	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—hematologic cancer	4.48e-06	2.71e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Epirubicin—hematologic cancer	4.37e-06	2.64e-05	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—hematologic cancer	4.36e-06	2.63e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—hematologic cancer	4.34e-06	2.62e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—hematologic cancer	4.34e-06	2.62e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Methotrexate—hematologic cancer	4.33e-06	2.62e-05	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—hematologic cancer	4.25e-06	2.57e-05	CcSEcCtD
Lansoprazole—Pruritus—Epirubicin—hematologic cancer	4.19e-06	2.53e-05	CcSEcCtD
Lansoprazole—Dizziness—Methotrexate—hematologic cancer	4.19e-06	2.53e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Epirubicin—hematologic cancer	4.06e-06	2.45e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—hematologic cancer	4.04e-06	2.44e-05	CcSEcCtD
Lansoprazole—Vomiting—Methotrexate—hematologic cancer	4.03e-06	2.43e-05	CcSEcCtD
Lansoprazole—Rash—Methotrexate—hematologic cancer	3.99e-06	2.41e-05	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—hematologic cancer	3.99e-06	2.41e-05	CcSEcCtD
Lansoprazole—Headache—Methotrexate—hematologic cancer	3.97e-06	2.4e-05	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—hematologic cancer	3.93e-06	2.38e-05	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—hematologic cancer	3.92e-06	2.37e-05	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—hematologic cancer	3.88e-06	2.34e-05	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—hematologic cancer	3.77e-06	2.28e-05	CcSEcCtD
Lansoprazole—Nausea—Methotrexate—hematologic cancer	3.76e-06	2.27e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—hematologic cancer	3.75e-06	2.27e-05	CcSEcCtD
Lansoprazole—Rash—Epirubicin—hematologic cancer	3.74e-06	2.26e-05	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—hematologic cancer	3.73e-06	2.26e-05	CcSEcCtD
Lansoprazole—Headache—Epirubicin—hematologic cancer	3.71e-06	2.24e-05	CcSEcCtD
Lansoprazole—Dizziness—Doxorubicin—hematologic cancer	3.63e-06	2.19e-05	CcSEcCtD
Lansoprazole—Nausea—Epirubicin—hematologic cancer	3.52e-06	2.13e-05	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—hematologic cancer	3.49e-06	2.11e-05	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—hematologic cancer	3.46e-06	2.09e-05	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—hematologic cancer	3.45e-06	2.09e-05	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—hematologic cancer	3.44e-06	2.08e-05	CcSEcCtD
Lansoprazole—Nausea—Doxorubicin—hematologic cancer	3.26e-06	1.97e-05	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	2.2e-06	3.22e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—UGT1A1—hematologic cancer	2.2e-06	3.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ENO2—hematologic cancer	2.19e-06	3.2e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CG—hematologic cancer	2.18e-06	3.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.17e-06	3.18e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NQO1—hematologic cancer	2.17e-06	3.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CD44—hematologic cancer	2.17e-06	3.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.14e-06	3.14e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTT1—hematologic cancer	2.14e-06	3.13e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—EP300—hematologic cancer	2.14e-06	3.13e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC22A1—hematologic cancer	2.14e-06	3.13e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CRABP1—hematologic cancer	2.14e-06	3.13e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.13e-06	3.11e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HMMR—hematologic cancer	2.12e-06	3.11e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—IDH2—hematologic cancer	2.12e-06	3.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTT1—hematologic cancer	2.12e-06	3.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.12e-06	3.1e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SDC1—hematologic cancer	2.09e-06	3.06e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2.09e-06	3.06e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALOX5—hematologic cancer	2.08e-06	3.05e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SDC1—hematologic cancer	2.07e-06	3.03e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.05e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYCS—hematologic cancer	2.05e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	2.04e-06	2.98e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CREBBP—hematologic cancer	2.02e-06	2.96e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NUP98—hematologic cancer	2.02e-06	2.95e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2e-06	2.93e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.99e-06	2.92e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.99e-06	2.91e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CG—hematologic cancer	1.99e-06	2.91e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.98e-06	2.9e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTP1—hematologic cancer	1.97e-06	2.88e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTEN—hematologic cancer	1.96e-06	2.87e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ADCY7—hematologic cancer	1.96e-06	2.87e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NCOA3—hematologic cancer	1.96e-06	2.87e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.95e-06	2.86e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NUP214—hematologic cancer	1.95e-06	2.85e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CA9—hematologic cancer	1.94e-06	2.84e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ACP5—hematologic cancer	1.94e-06	2.84e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CD44—hematologic cancer	1.93e-06	2.83e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NQO1—hematologic cancer	1.93e-06	2.83e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.93e-06	2.82e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CD—hematologic cancer	1.92e-06	2.81e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.92e-06	2.8e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.91e-06	2.79e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.91e-06	2.79e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MTR—hematologic cancer	1.91e-06	2.79e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ALB—hematologic cancer	1.89e-06	2.77e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.89e-06	2.77e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CD44—hematologic cancer	1.89e-06	2.76e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NQO1—hematologic cancer	1.89e-06	2.76e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—EP300—hematologic cancer	1.87e-06	2.74e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.87e-06	2.74e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ENO2—hematologic cancer	1.87e-06	2.73e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ABCB1—hematologic cancer	1.87e-06	2.73e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CREBBP—hematologic cancer	1.84e-06	2.7e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.83e-06	2.68e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYCS—hematologic cancer	1.83e-06	2.68e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—IDH1—hematologic cancer	1.82e-06	2.67e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	1.82e-06	2.66e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTT1—hematologic cancer	1.81e-06	2.65e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3R1—hematologic cancer	1.81e-06	2.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NCOR1—hematologic cancer	1.81e-06	2.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTM1—hematologic cancer	1.81e-06	2.65e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.81e-06	2.64e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.8e-06	2.64e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.8e-06	2.64e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TXN—hematologic cancer	1.8e-06	2.64e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYCS—hematologic cancer	1.79e-06	2.61e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.78e-06	2.61e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NQO1—hematologic cancer	1.78e-06	2.6e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CD44—hematologic cancer	1.78e-06	2.6e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—HSP90AA1—hematologic cancer	1.77e-06	2.6e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SDC1—hematologic cancer	1.77e-06	2.59e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.77e-06	2.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CD44—hematologic cancer	1.76e-06	2.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NQO1—hematologic cancer	1.76e-06	2.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.75e-06	2.56e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CD—hematologic cancer	1.75e-06	2.56e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.73e-06	2.53e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ALB—hematologic cancer	1.72e-06	2.52e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.71e-06	2.5e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.7e-06	2.48e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.69e-06	2.48e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYCS—hematologic cancer	1.68e-06	2.46e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CB—hematologic cancer	1.67e-06	2.45e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.67e-06	2.45e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.67e-06	2.44e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYCS—hematologic cancer	1.67e-06	2.44e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.66e-06	2.43e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.66e-06	2.43e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.66e-06	2.43e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.65e-06	2.41e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.65e-06	2.41e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3R1—hematologic cancer	1.65e-06	2.41e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.64e-06	2.39e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTP1—hematologic cancer	1.61e-06	2.36e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.61e-06	2.35e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—MTHFR—hematologic cancer	1.6e-06	2.34e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.6e-06	2.34e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—hematologic cancer	1.58e-06	2.32e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTP1—hematologic cancer	1.57e-06	2.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.56e-06	2.28e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NUP98—hematologic cancer	1.56e-06	2.28e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ABCB1—hematologic cancer	1.53e-06	2.23e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CB—hematologic cancer	1.52e-06	2.23e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.51e-06	2.21e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.51e-06	2.21e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CD44—hematologic cancer	1.51e-06	2.2e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NQO1—hematologic cancer	1.51e-06	2.2e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NUP214—hematologic cancer	1.5e-06	2.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.49e-06	2.18e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.48e-06	2.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NCOR1—hematologic cancer	1.48e-06	2.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTM1—hematologic cancer	1.48e-06	2.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.48e-06	2.16e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.47e-06	2.15e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MTR—hematologic cancer	1.47e-06	2.15e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.47e-06	2.15e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.47e-06	2.15e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTM1—hematologic cancer	1.45e-06	2.12e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NCOR1—hematologic cancer	1.45e-06	2.12e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTEN—hematologic cancer	1.45e-06	2.12e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ENO2—hematologic cancer	1.44e-06	2.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYCS—hematologic cancer	1.43e-06	2.09e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.42e-06	2.08e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.42e-06	2.07e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.41e-06	2.06e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.4e-06	2.05e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.4e-06	2.05e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.39e-06	2.04e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—hematologic cancer	1.38e-06	2.02e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—hematologic cancer	1.38e-06	2.02e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SDC1—hematologic cancer	1.37e-06	2e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.36e-06	1.99e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.36e-06	1.99e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.35e-06	1.98e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.35e-06	1.98e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CG—hematologic cancer	1.34e-06	1.97e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTEN—hematologic cancer	1.32e-06	1.92e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.31e-06	1.92e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.29e-06	1.89e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—hematologic cancer	1.29e-06	1.89e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—MTHFR—hematologic cancer	1.28e-06	1.87e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.27e-06	1.87e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.26e-06	1.84e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—hematologic cancer	1.25e-06	1.84e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CREBBP—hematologic cancer	1.25e-06	1.82e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.23e-06	1.8e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.22e-06	1.78e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.2e-06	1.76e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.19e-06	1.75e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.19e-06	1.74e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.18e-06	1.73e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ALB—hematologic cancer	1.17e-06	1.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CD44—hematologic cancer	1.16e-06	1.7e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NQO1—hematologic cancer	1.16e-06	1.7e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.15e-06	1.69e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.15e-06	1.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.15e-06	1.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.14e-06	1.67e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—hematologic cancer	1.13e-06	1.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.12e-06	1.63e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.1e-06	1.61e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYCS—hematologic cancer	1.1e-06	1.61e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.09e-06	1.6e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.08e-06	1.59e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.07e-06	1.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ALB—hematologic cancer	1.07e-06	1.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.05e-06	1.54e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.03e-06	1.51e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.02e-06	1.5e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.02e-06	1.49e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.02e-06	1.49e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—hematologic cancer	1.02e-06	1.49e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.01e-06	1.48e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1e-06	1.47e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CREBBP—hematologic cancer	9.96e-07	1.46e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.7e-07	1.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CD—hematologic cancer	9.67e-07	1.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALB—hematologic cancer	9.55e-07	1.4e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CB—hematologic cancer	9.45e-07	1.38e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CD—hematologic cancer	9.44e-07	1.38e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CREBBP—hematologic cancer	9.38e-07	1.37e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALB—hematologic cancer	9.32e-07	1.36e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CREBBP—hematologic cancer	9.3e-07	1.36e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—hematologic cancer	9.28e-07	1.36e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCB1—hematologic cancer	9.18e-07	1.34e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3R1—hematologic cancer	9.13e-07	1.34e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.99e-07	1.32e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3R1—hematologic cancer	8.91e-07	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NCOR1—hematologic cancer	8.91e-07	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTM1—hematologic cancer	8.91e-07	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTEN—hematologic cancer	8.9e-07	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CD—hematologic cancer	8.9e-07	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CD—hematologic cancer	8.82e-07	1.29e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALB—hematologic cancer	8.78e-07	1.29e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALB—hematologic cancer	8.71e-07	1.27e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.57e-07	1.25e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—hematologic cancer	8.49e-07	1.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CB—hematologic cancer	8.43e-07	1.23e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3R1—hematologic cancer	8.4e-07	1.23e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—hematologic cancer	8.33e-07	1.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3R1—hematologic cancer	8.33e-07	1.22e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CB—hematologic cancer	8.23e-07	1.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTEN—hematologic cancer	8.16e-07	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CREBBP—hematologic cancer	7.95e-07	1.16e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.87e-07	1.15e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—hematologic cancer	7.78e-07	1.14e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.75e-07	1.13e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CB—hematologic cancer	7.69e-07	1.12e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—hematologic cancer	7.58e-07	1.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.54e-07	1.1e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALB—hematologic cancer	7.44e-07	1.09e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTEN—hematologic cancer	7.29e-07	1.07e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3R1—hematologic cancer	7.12e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTEN—hematologic cancer	7.11e-07	1.04e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—hematologic cancer	6.95e-07	1.02e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—hematologic cancer	6.78e-07	9.92e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTEN—hematologic cancer	6.7e-07	9.81e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTEN—hematologic cancer	6.64e-07	9.72e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.62e-07	9.68e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.57e-07	9.61e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—hematologic cancer	6.39e-07	9.35e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—hematologic cancer	6.34e-07	9.27e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—hematologic cancer	6.28e-07	9.19e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.13e-07	8.98e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.82e-07	8.51e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—hematologic cancer	5.76e-07	8.43e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALB—hematologic cancer	5.74e-07	8.4e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTEN—hematologic cancer	5.68e-07	8.31e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.49e-07	8.04e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—hematologic cancer	5.41e-07	7.92e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—hematologic cancer	5.14e-07	7.52e-06	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—hematologic cancer	5.13e-07	7.51e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.07e-07	7.42e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—hematologic cancer	5.02e-07	7.34e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.73e-07	6.92e-06	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—hematologic cancer	4.7e-07	6.88e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—hematologic cancer	4.69e-07	6.86e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTEN—hematologic cancer	4.38e-07	6.41e-06	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—hematologic cancer	4.2e-07	6.14e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—hematologic cancer	4.18e-07	6.11e-06	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—hematologic cancer	4.1e-07	6e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—hematologic cancer	4e-07	5.86e-06	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—hematologic cancer	3.86e-07	5.65e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—hematologic cancer	3.83e-07	5.6e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—hematologic cancer	3.27e-07	4.79e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.09e-07	4.52e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—hematologic cancer	2.52e-07	3.69e-06	CbGpPWpGaD
